Standards for Securing the Drug Supply Chain - Standardized Numerical Identification for Prescription Drug PackagesGuidance for Industry - Final Guidance
Printer-Friendly Version (PDF - 50 KB)1
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM206075.pdfAdditional copies are available from:
Office of Training and Communications
Division of Drug Information, WO51, Room 2201
10903 New Hampshire Ave.
Silver Spring, MD 20993
Phone: 301-796-3400; Fax: 301-847-8714
druginfo@fda.hhs.gov
Guidances (Drugs)2
and/or
Office of Communication, Outreach, and
Development, HFM-40
Center for Biologics Evaluation and Research
Food and Drug Administration
1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448
(Tel) 800-835-4709 or 301-827-1800
ocod@fda.hhs.gov
Biologics Guidances3
and/or
Office of Policy
Office of the Commissioner
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993
Phone: 301-796-4830
U.S. Department of Health and Human Services
Food and Drug Administration
Office of the Commissioner (OC)
Center for Drug Evaluation and Research
Center for Biologics Evaluation and Research
Office of Regulatory Affairs
March 2010
TABLE OF CONTENTS
----------
I. INTRODUCTION
II. BACKGROUND
A. Food and Drug Administration Amendments Act of 2007
B. Scope of this Guidance
III. STANDARDIZED NUMERICAL IDENTIFIERS
A. What should be designated as a package-level SNI for most prescription drugs?
B. What should be designated as a package-level SNI for certain biological products?
C. Does the SNI include expiration date and/or lot or batch number?
D. Why did FDA select the serialized NDC for package-level SNI for most prescription drugs?
E. Should the SNI be in human- and machine-readable forms?
F. Is the SNI that FDA is recommending compatible with international standards?open here to see the full-text (large):
http://www.fda.gov/RegulatoryInformation/Guidances/ucm125505.htm
No hay comentarios:
Publicar un comentario